MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
-
34th Annual Oppenheimer Healthcare Life Sciences Conference
- Format: Presentation
- Date and Time: Tuesday, February 13, 2024 at 10:00 am EST
- Webcast Link: 34th Annual Oppenheimer Healthcare Life Sciences Conference
Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine, and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Cboe Canada exchange (formerly the NEO Exchange) under the symbol MMED.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207998518/en/
For Media: media@mindmed.co
For Investors: ir@mindmed.co
Source: MindMed